Pharmacodynamic efficacy
Stroke
SECONDARY, CEREBRAL INFARCTION, STROKE
Median C5a concentration in CSF on day 3 was 251 pg/ml [IQR: 103–402] in the intervention group and 371 pg/ml [IQR: 131–534] in the control group (Primary and secondary outcomes.IQR: interquartile range; NIHSS: National Institutes of Health Stroke Scale; WFNS: World Federation of Neurosurgical Societies; Cerebral infarction: any region of diffusion restriction on diffusion-weighted imaging (MRI); MoCA: Montreal Cognitive Assessment; EQ-5D-5L and EQ-VAS: quality of life assessments; mRS: modified Rankin Scale.In both the per-protocol and intention-to-treat analysis.C5a concentration in CSF on day 3.CSF: cerebrospinal fluid.Points in the graph represent individual patient data. The horizontal line represents the median concentration in each group.